- Rating
- 3
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 3
Read review
Paper summary
The paper targets a key failure in antibody–antigen co-folding: models often repeatedly dock antibodies to the wrong epitope, and additional sampling does not reliably fix this. It introduces CAST, a training-free diffusion-steering method that explicitly explores candidate binding sites while amortizing multiple site hypotheses and MSA conditionings in a single particle pool, reducing exploration cost from to . The authors also provide a reference-free epitope map and a theoretical result showing that site steering preserves the model’s pose distribution conditional on a site.
Empirically, CAST improves mean max DockQ from 0.322 to 0.373 and acceptable-pose coverage from 26/50 to 36/50 on CFA50 at matched sampling budgets, with gains concentrated on difficult targets. On 21 especially hard targets, it succeeds on 18/21 vs. 9/21 for Best-of-N and scales better with additional compute. Comparisons to four steering baselines, ablations, and transfer to a second backbone further support that directed site exploration, rather than diversity alone, drives the gains.
Critical strengths
-
Novel and well-motivated approach to a consequential failure mode. CAST directly targets site coverage—cases where co-folding models fail to sample the correct epitope at all—rather than relying on additional sampling or pose diversity. The distinction is important because no downstream ranker can recover a correct complex that was never sampled. The training-free formulation and amortization also make the contribution practically meaningful.
-
Strong, targeted empirical validation. At matched budgets, CAST substantially improves difficult cases (36/50 vs. 26/50 acceptable CFA50 targets; 18/21 vs. 9/21 on the hard set), with ablations and a second-backbone experiment supporting the proposed mechanism rather than generic diversification. This makes the central claim convincing and is the strongest evidence supporting acceptance.
Critical weaknesses
- The strongest gains are concentrated on a deliberately difficult regime. CAST provides little improvement on targets that Best-of-N already solves reliably, while the separate 21-target benchmark is explicitly selected for cases where the base model performs poorly. This makes the method compelling as a targeted remedy, but leaves its broader benefit across representative antibody–antigen prediction workloads less established.
- Performance remains strongly dependent on candidate-site quality. The oracle-map ablation improves mean max DockQ from 0.373 to 0.484, indicating substantial headroom attributable to site proposal rather than steering itself. Because the practical reference-free map can miss or poorly localize the true epitope, this dependency is a consequential limitation of the end-to-end method.
Questions for authors
Clarification requests:
-
The overall CAST–Feynman–Kac comparison is not statistically significant (), although CAST is significantly better on the subset of targets not reliably solved by BoN. Could the authors clarify whether the claimed advantage over alternative steering methods is intended specifically for this difficult regime, rather than overall?
-
The oracle-map ablation improves mean max DockQ substantially (0.373 → 0.484). Could the authors further quantify how CAST performance varies with candidate-map accuracy, particularly when the true epitope is poorly covered or absent from the candidate set? This would clarify whether candidate-site generation or steering is the primary practical bottleneck.
Suggestion for future work: Improving the reference-free candidate-site map, potentially using stronger epitope predictors, appears to be a promising direction given the large oracle-map headroom.
4 comments
Thank you again for your review. We have posted a detailed response and new measurements addressing the points you raised. As the discussion period is going to a close, we would be grateful to know whether our response resolves your concerns, and we are happy to provide anything further.
Thanks to the authors for these explanations. I already (weak) accept the paper, so I retain my score.
Thank you for reading our response. We are glad the concerns are addressed.
Your W1 and Q1 changed the reporting. The paired result on the 29 targets the base model does not reliably solve is now in the results section. The bootstrap intervals are in a new appendix table, for both Best-of-N and Feynman Kac. The claim is scoped to that regime in the text. That is what your Q1 asked.
Your W2 and Q2 added a table. It bins outcome by candidate map error. A Best-of-N control sits beside it, so a reader can see how much of the binning is target difficulty.
We also acted on your suggestion for future work. We ran an external epitope predictor over all 50 antigens. It now sits beside our own map in the candidate map table.
Thank you again for the care you gave the paper.
We thank the reviewer for a reading that matches the paper's claims closely. Both weaknesses are properties we agree the paper has.
These are one phenomenon. The effect is concentrated by difficulty group, which Proposition 1 predicts, since the tilt cannot move a pose already at the right site. CFA50 is difficulty balanced, 16 / 13 / 21, and the solved group is reported precisely to show CAST does not damage it. The paired tests are Table 1 and Table 2, with intervals added here (stated plainly in section 4.2).
Both comparisons are significant on the 29 targets the base model does not reliably solve, with both intervals clear of zero, and neither is on the 21 it solves. The Best-of-N difference there is the do no harm result, and FK's apparent lead is not established either, its interval straddling zero.
That explains why the pooled FK comparison returns 0.104 where Best-of-N returns 0.012, despite the same pattern. FK is the stronger baseline at both ends, leading CAST less on the 29 and taking more back on the 21, so the same cancellation leaves a smaller margin. Averaging the two groups gives +0.051 against Best-of-N and +0.036 against FK, an effect 30% smaller on the same 50 targets, which is what moves the pooled p across the threshold (-0.003, 0.079). The pooled test therefore measures the composition of a difficulty balanced benchmark rather than the absence of an effect.
The mechanism behind that split is resampling. FK proposes from the unmodified base model and resamples on the reward, so it can only concentrate mass the base model already puts somewhere. Where the base model already places mass on the right site, concentrating it there is exactly right and FK wins, which is the solved row. Where it places almost none there is nothing for the reward to select, and concentrating harder makes it worse, which is the failed row. Resampling can only redistribute mass, and creating it where the base model puts none is what the gradient does, which is the transport the paper means. That is why we also have to trade-off between them.
Agreed that the map sets a ceiling, and here is the dependence measured rather than bounded by the oracle contrast. New table shows targets binned by distance from the true epitope to the nearest map candidate.
A better map is better, but an accurate map is not what the method needs. Accuracy helps monotonically, 0.425 under 6 Å against 0.302 at 6 to 12 Å, but the gain over Best-of-N runs the other way, +0.034 against +0.099, since where the map is right the base model often reaches the site unaided. The requirement is a candidate within about 12 Å, not a correct one, so the dependence is weaker than the oracle map ablation alone suggests. The outer bin holds only 2 targets, so we draw no conclusion from it.
As a control, Spearman rho between map error and outcome is −0.477 for CAST and −0.457 for Best-of-N. Best-of-N never sees the map, so its outcome is a map free measure of how hard the target is, and map error tracks it just as closely. Map error is therefore largely a proxy for target difficulty, and almost none of CAST's correlation is dependence on the map.
We agree, and an accurate epitope predictor is also an open problem.